Darrell Tan

1

Article

0

Comments
  • Clinician-Scientist, St. Michael’s Hospital; Associate Professor, Faculty of Medicine, University of Toronto
The HIV prevention drug cabotegravir, which is delivery by injection every eight weeks, is not yet available in Canada. (Shutterstock)

Long‑acting injectable PrEP is a big step forward in HIV prevention

Michael Montess, Western University; Darrell Tan, University of Toronto, and Nathan John Lachowsky, University of Victoria

The next step in HIV prevention — long-acting injectable pre-exposure prophylaxis (PrEP) — is not yet available in Canada, a year after its approval in the U.S.

Contact Darrell for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision